archive-ca.com » CA » H » HEMOPHILIA.CA

Total: 850

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Hemophilia.ca | Canadian Hemophilia Society - Société Canadienne de l'Hémophilie
    The Canadian Hemophilia Society is committed to improve the health and quality of life of all people with inherited bleeding disorders and ultimately to find a cure Our Vision A world free from the pain and suffering of inherited bleeding disorders Notre mission La Société canadienne de l hémophilie est déterminée à améliorer l état de santé et la qualité de vie de toutes les personnes atteintes de troubles héréditaires

    Original URL path: http://www.hemophilia.ca/ (2014-10-09)
    Open archived version from archive


  • Home - Canadian Hemophilia Society
    General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment Centre partnerships ended recently Canadian Hemophilia Society International Projects Fund Canadian Organizational Twins Recently closed twinning partnerships Treatment Centres British Columbia Alberta Saskatchewan Manitoba Ontario Quebec New Brunswick Prince Edward Island Nova Scotia Newfoundland and Labrador HCV HIV Hepatitis C and HIV Compensation I am a survivor HCV treatment support for 1986 1990 claimants National Endowment Fund Scholarship University of Ottawa Criminalization of HIV Non Disclosure HIV Know your rights US travel ban lifted World Hepatitis Day Recommendations for a Canadian Hepatitis C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards of Care Symptoms Treatment Options for Hepatitis C Liver transplantation Youth Web About Us News Feed To Contact Us Commemoration of the Tainted Blood Tragedy Tree of Life Commemorations Canadian Blood Services November 26 2007 Héma Québec October 9 2008 CHS Newfounland Labrador Chapter Commemoration 2008 2009 Hemophilia Saskatchewan Commemoration 2009 CHS British Columbia Chapter Commemoration 2009 CHS Prince Edward Island Chapter Commemoration 2009 Hemophilia Ontario Commemoration 2009 Hemophilia Ontario Commemoration 2010 CHS Manitoba Chapter Commemoration 2010 Hemophilia Ontario Commemoration 2011 New Brunswick Chapter Commemoration 2012 Hemophilia Ontario Commemoration 2012 Hemophilia Saskatchewan Commemoration 2012 Hemophilia Saskatchewan Commemoration 2103 Hemophilia Ontario Commemoration 2013 Hemophilia Alberta Commemoration 2014 Media Room Press releases 2009 2011 Press releases 2006 2008 Search Français Our Partners Home CHS e News CHS on facebook and YouTube Second study suggests higher risk of inhibitors with Kogenate Helixate in previously untreated patients with hemophilia A MONTREAL October 6 2014 A second study in less than two years suggests a higher risk of inhibitors in previously untreated hemophilia A patients PUPs with Kogenate FS and Helixate FS compared to other recombinant FVIII products The study by Calvez et al of more than 300 boys in France published in the journal Blood on September 24 2014 found that the risk of developing inhibitors was close to 60 higher In January 2013 the Research of Determinants of Inhibitor Development RODIN study group also reported a similarly higher risk of inhibitor development in PUPs treated with this second generation full length rFVIII Kogenate FS Helixate FS compared to all other FVIII products At that time the Association of Hemophilia Clinic Directors of Canada recommended to its members that they consider these findings as a factor in their decision making regarding product choice for newly diagnosed PUPs with severe hemophilia A The RODIN study was reviewed by regulators and in December 2013 the European Medicines Agency s EMA concluded that the benefits of Kogenate FS Helixate NexGen Helixate FS in Canada continue to outweigh their risks in PUPs with hemophilia A Following the most recent paper however the World Federation of Hemophilia s Therapeutic Products Safety Supply and Availability Committee TPSSAC issued a statement which said Based on the available published data it may be prudent where other safe clotting factor concentrates are available to consider not using Kogenate FS Helixate NexGen for newly diagnosed PUPs with severe hemophilia A The WFH TPSSAC also stated There is no evidence of a higher risk of inhibitors with this product in previously treated patients Click here for the complete statement Regulatory agencies such as the EMA and the U S FDA are evaluating this latest data on inhibitor development Both the CHS Blood Safety and Supply Committee and the WFH TPSSAC are monitoring developments Please check on the CHS and WFH Web sites for updates NEW CHS resources about HCV treatment support for 1986 1990 claimants Accessing treatments for hepatitis C through the Hepatitis C January 1 1986 July 1 1990 Class Actions Settlement What you need to know If you are a patient who received tainted blood or blood products and a registered claimant of the Hepatitis C HCV 1986 1990 Class Actions Settlement now is a good time to speak to your doctor about new treatments for HCV Treatment has progressed significantly and it may be the right time for you to seek a cure People who are approved claimants under the Hepatitis C January 1 1986 July 1 1990 Class Actions Settlement may be reimbursed for their costs for treatments and generally accepted hepatitis C medications that are not recoverable under any public or private health care plan Moreover thanks to a collaborative effort between the CHS and Gilead Health Sciences Canada The Momentum Support Program can now provide upfront payments to those eligible for the high cost treatment Sovaldi sofosbuvir while the

    Original URL path: http://www.hemophilia.ca/en/ (2014-10-09)
    Open archived version from archive

  • Accueil - La Société canadienne de l'hémophilie
    2014 Projets de recherche subventionnés en 2013 Projets de recherche subventionnés en 2012 Projets de recherche subventionnés en 2011 Projets de recherche subventionnés en 2010 Projets de recherche subventionnés en 2009 Projets de recherche subventionnés en 2008 Projets de recherche subventionnés en 2007 Projets de recherche subventionnés en 2006 Projets de recherche subventionnés en 2005 Programme de recherche psychosociale SCH Novo Nordisk Critères d admissibilité Conditions générales Formulaire de demande de bourse Projet de recherche subventionné en 2014 Programme de fellowship sur l hémostase Critères d admissibilité Conditions générales Formulaire de demande de bourse Projet de recherche subventionné en 2014 Projet de recherche subventionné en 2013 Projet de recherche subventionné en 2012 Projet de recherche subventionné en 2011 Projet de recherche subventionné en 2010 Projet de recherche subventionné en 2009 Projet de recherche subventionné en 2008 Projet de recherche subventionné en 2007 Projet de recherche subventionné en 2006 Projet de recherche subventionné en 2005 Programme de bourses SCH Baxter Critères d admissibilité Conditions générales Formulaire de demande de bourse Projets de recherche subventionnés en 2014 Projet de recherche subventionné en 2013 Possibilités de participer à la recherche Possibilités de participer à des études de marketing Développement international Bourse jeunesse Karttik Shah Projets de jumelage international Fonds des projets internationaux de la Société canadienne de l hémophilie Jumelages canadiens Centres de traitement Jumelages de centres de traitement ayant pris fin récemment Jumelages canadiens Organisations Jumelages ayant pris fin récemment Centres de traitement Colombie Britannique Alberta Saskatchewan Manitoba Ontario Québec Nouveau Brunswick Île du Prince Édouard Nouvelle Écosse Terre Neuve et Labrador Hépatite C VIH L indemnisation des personnes ayant contracté l hépatite C ou le VIH Je suis un survivant Soutien pour le traitement contre le VHC des requérants 1986 1990 Fonds de dotation national Bourse de l Université d Ottawa Criminalisation du non dévoilement de la séropositivité au VIH HIV Connaître ses droits Restrictions au voyage aux É U levées Journée mondiale contre l hépatite Recommandations pour une stratégie canadienne sur l hépatite C 2005 Hépatite C Livret d information Aspects psychosociaux Co infection Hépatite C et VIH Diagnostic Hygiène de vie Introduction à l hépatite C Le mot de la fin Médecines douces Normes de soins Obtenir un traitement Options de traitement de l hépatite C Symptômes Greffe du foie Web Jeunes À propos de nous Nouvelles Pour nous joindre Commémoration de la tragédie du sang contaminé Cérémonies d arbre de vie Société canadienne du sang 26 novembre 2007 Héma Québec 9 octobre 2008 SCH Section Terre Neuve et Labrador Commémoration 2008 et 2009 Hémophilie Saskatechewan Commémoration 2009 SCH Section Colombie Britannique Commémoration 2009 SCH Section Île du Prince Édouard Commémoration 2009 Hémophilie Ontario Commémoration 2009 Hémophilie Ontario Commémoration 2010 Section provinciale du Manitoba SCH Commémoration 2010 Hémophilie Ontario Commémoration 2011 Section Nouveau Brunswick Commémoration 2012 Hémophilie Ontario Commémoration 2012 Hémophilie Saskatchewan Commémoration 2012 Hémophilie Saskatchewan Commémoration 2013 Hémophilie Ontario Commémoration 2013 Hémophilie Alberta Commémoration 2014 Salle de presse Communiqués de presse 2009 2011 Communiqués de presse 2006 2008 Recherche English Nos partenaires Accueil Info SCH La SCH sur facebook et YouTube Une deuxième étude évoque un risque plus élevé d inhibiteurs avec Kogenate Helixate chez les patients atteints d hémophilie A grave non préalablement traités MONTRÉAL Le 6 octobre 2014 Selon une deuxième étude publiée sur la question en moins de deux ans il existerait un risque plus élevé d inhibiteurs avec Kogenate FS et Helixate FS chez les patients atteints d hémophilie A grave non préalablement traités par rapport aux autres produits de remplacement de facteur VIII recombinant L étude publiée par Calvez et al dans le journal Blood le 24 septembre 2014 qui s est déroulée en France et portait sur plus de 300 garçons fait état d un risque de près de 60 supérieur à l égard des inhibiteurs En janvier 2013 le groupe d étude RODIN pour Research of Determinants of Inhibitor Development avait également révélé que les patients non préalablement traités recevant ces produits de facteur VIII recombinant de pleine longueur et de seconde génération Kogenate FS et Helixate FS présentaient un risque plus élevé de développement d inhibiteurs par rapport à ceux utilisant d autres concentrés de facteur VIII recombinant L Association canadienne des directeurs des cliniques d hémophilie avait alors recommandé à ses membres de tenir compte de ces résultats au moment de décider d un schéma thérapeutique pour les patients atteints d hémophilie A grave récemment dépistés et non préalablement traités L étude RODIN a été examinée par des organismes de réglementation et en décembre 2013 l Agence européenne des médicaments EMA a confirmé les recommandations selon lesquelles les bénéfices des produits Kogenate FS et Helixate NexGen Helixate FS au Canada continuaient de l emporter sur les risques chez les patients atteints d hémophilie A grave non préalablement traités Toutefois depuis la publication du récent article le Comité sur la sécurité et l accessibilité des produits de traitement TPSSA de la Fédération mondiale de l hémophilie FMH a déclaré par voie de communiqué En fonction des données publiées disponibles il peut être prudent lorsque d autres concentrés de facteurs de coagulation sûrs sont à disposition d envisager de ne pas utiliser Kogenate FS Bayer Helixate NexGen pour les patients atteints d hémophilie A grave récemment dépistés et non traités préalablement Le Comité de la FMH a aussi ajouté Aucun élément probant ne démontre de risque accru d inhibiteurs avec ce produit chez les patients déjà traités On peut consulter la déclaration intégrale sur le site web de la FMH Des organismes de réglementation tels que la Food and Drug Administration FDA des États Unis et l EMA examinent présentement ces dernières données concernant le développement d inhibiteurs Le Comité de la sûreté du sang et de l approvisionnement sanguin de la SCH et son homologue de la FMH surveillent la situation de près Des mises à jour seront publiées sur le site web de la SCH et celui de la FMH NOUVELLE ressource de la SCH en lien avec le

    Original URL path: http://www.hemophilia.ca/fr/ (2014-10-09)
    Open archived version from archive



  • About the CHS - Canadian Hemophilia Society
    is hemophilia The history of hemophilia The clotting problem in hemophilia Heredity of hemophilia The symptoms of hemophilia The diagnosis of hemophilia The treatment of hemophilia Comprehensive hemophilia care Factor replacement therapy Other treatments The complications of hemophilia Blood borne infections Inhibitors Joint damage Precautions Carriers of hemophilia A and B Von Willebrand disease Preface Acknowledgements An Introduction to von Willebrand disease Types of von Willebrand disease Heredity of von Willebrand disease Symptoms of von Willebrand disease Diagnosis of von Willebrand disease Treatment options for von Willebrand disease Introduction Recommended Treatments for Men and Women Not Recommended Treatments Recommended Treatments for Women with Gynecological Complications Living with von Willebrand disease Comprehensive care Safety of Blood Products Nose bleeds Conception Pregnancy and Childbirth Medication to Be Avoided Exercise Fitness and Sports Child Care and Schooling Employment Insurance Travelling Medical Identification Final word Where to get more information Hemophilia Bleeding Disorder Treatment Centres Glossary Bibliography Other factor deficiencies Factor I deficiency Fibrinogen deficiency Factor II deficiency Prothrombin deficiency Factor V deficiency Combined factor V and factor VIII deficiency Factor VII deficiency Factor X deficiency Factor XI deficiency Hemophilia C Factor XII deficiency Factor XIII deficiency Summary Chart Platelet function disorders Introduction Symptoms of platelet function disorders Diagnosis of platelet function disorders Types of platelet function disorders Treatment of platelet function disorders Precautions PDF documents Clotting factor concentrates Women Inherited bleeding disorders affecting women Symptoms Diagnosis Inheritance Medical treatment options for menorrhagia and other symptoms Gynaecological treatment options for menorrhagia Precautions for pregnant women Staying healthy Bleeding disorder treatment centres Educational resources Stories from women and girls who bleed too much About the CHS Support and Education Passport to well being Destination fitness Home care The road to independence Roadmap for managing pain Navigating the emergency department Bon Voyage Travelling with a bleeding disorder Charting Your Course PEP Parents Empowering Parents program Vocational assessment tool Career planning and scholarship links Scholarship Program Federal and Provincial Support Programs Insurance coverage Educational Material Printed documents Bleeding disorders in women Carriers of hemophilia A or B Hemophilia Hepatitis C HIV Inhibitors Physical activity and sports Platelet function disorders Rare factor deficiencies Relevant to all bleeding disorders Resources for children Von Willebrand disease Videos Care and Treatment Emergency Care Pain Management Nursing Physiotherapy Introduction Constitution of the Canadian Physiotherapists in Hemophilia Care CPHC Standards of Physiotherapy Care and Assessment Selected Journal Articles Educational material Bibliography Other resources Social Work Community Partners and Links Practice Guidelines Mission Services Interventions Standards of Practice Comprehensive Care Standards Safe Secure Blood Supply Products in the pipeline CHS Policy on Paid Plasma Donations Report Cards on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD

    Original URL path: http://www.hemophilia.ca/en/about-the-chs/ (2014-10-09)
    Open archived version from archive

  • Our Strategic Plan - Canadian Hemophilia Society
    Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment Centre partnerships ended recently Canadian Hemophilia Society International Projects Fund Canadian Organizational Twins Recently closed twinning partnerships Treatment Centres British Columbia Alberta Saskatchewan Manitoba Ontario Quebec New Brunswick Prince Edward Island Nova Scotia Newfoundland and Labrador HCV HIV Hepatitis C and HIV Compensation I am a survivor HCV treatment support for 1986 1990 claimants National Endowment Fund Scholarship University of Ottawa Criminalization of HIV Non Disclosure HIV Know your rights US travel ban lifted World Hepatitis Day Recommendations for a Canadian Hepatitis C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards of Care Symptoms Treatment Options for Hepatitis C Liver transplantation Youth Web About Us News Feed To Contact Us Commemoration of the Tainted Blood Tragedy Tree of Life Commemorations Canadian Blood Services November 26 2007 Héma Québec October 9 2008 CHS Newfounland Labrador Chapter Commemoration 2008 2009 Hemophilia Saskatchewan Commemoration 2009 CHS British Columbia Chapter Commemoration 2009 CHS Prince Edward Island Chapter Commemoration 2009 Hemophilia Ontario Commemoration 2009 Hemophilia Ontario Commemoration 2010 CHS Manitoba Chapter Commemoration 2010 Hemophilia Ontario Commemoration 2011 New Brunswick

    Original URL path: http://www.hemophilia.ca/en/about-the-chs/our-strategic-plan/ (2014-10-09)
    Open archived version from archive

  • Membership - Canadian Hemophilia Society
    Comprehensive care Safety of Blood Products Nose bleeds Conception Pregnancy and Childbirth Medication to Be Avoided Exercise Fitness and Sports Child Care and Schooling Employment Insurance Travelling Medical Identification Final word Where to get more information Hemophilia Bleeding Disorder Treatment Centres Glossary Bibliography Other factor deficiencies Factor I deficiency Fibrinogen deficiency Factor II deficiency Prothrombin deficiency Factor V deficiency Combined factor V and factor VIII deficiency Factor VII deficiency Factor X deficiency Factor XI deficiency Hemophilia C Factor XII deficiency Factor XIII deficiency Summary Chart Platelet function disorders Introduction Symptoms of platelet function disorders Diagnosis of platelet function disorders Types of platelet function disorders Treatment of platelet function disorders Precautions PDF documents Clotting factor concentrates Women Inherited bleeding disorders affecting women Symptoms Diagnosis Inheritance Medical treatment options for menorrhagia and other symptoms Gynaecological treatment options for menorrhagia Precautions for pregnant women Staying healthy Bleeding disorder treatment centres Educational resources Stories from women and girls who bleed too much About the CHS Support and Education Passport to well being Destination fitness Home care The road to independence Roadmap for managing pain Navigating the emergency department Bon Voyage Travelling with a bleeding disorder Charting Your Course PEP Parents Empowering Parents program Vocational assessment tool Career planning and scholarship links Scholarship Program Federal and Provincial Support Programs Insurance coverage Educational Material Printed documents Bleeding disorders in women Carriers of hemophilia A or B Hemophilia Hepatitis C HIV Inhibitors Physical activity and sports Platelet function disorders Rare factor deficiencies Relevant to all bleeding disorders Resources for children Von Willebrand disease Videos Care and Treatment Emergency Care Pain Management Nursing Physiotherapy Introduction Constitution of the Canadian Physiotherapists in Hemophilia Care CPHC Standards of Physiotherapy Care and Assessment Selected Journal Articles Educational material Bibliography Other resources Social Work Community Partners and Links Practice Guidelines Mission Services Interventions Standards of Practice Comprehensive Care Standards Safe Secure Blood Supply Products in the pipeline CHS Policy on Paid Plasma Donations Report Cards on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects

    Original URL path: http://www.hemophilia.ca/en/about-the-chs/membership/ (2014-10-09)
    Open archived version from archive

  • Case for Support - Canadian Hemophilia Society
    Precautions Carriers of hemophilia A and B Von Willebrand disease Preface Acknowledgements An Introduction to von Willebrand disease Types of von Willebrand disease Heredity of von Willebrand disease Symptoms of von Willebrand disease Diagnosis of von Willebrand disease Treatment options for von Willebrand disease Introduction Recommended Treatments for Men and Women Not Recommended Treatments Recommended Treatments for Women with Gynecological Complications Living with von Willebrand disease Comprehensive care Safety of Blood Products Nose bleeds Conception Pregnancy and Childbirth Medication to Be Avoided Exercise Fitness and Sports Child Care and Schooling Employment Insurance Travelling Medical Identification Final word Where to get more information Hemophilia Bleeding Disorder Treatment Centres Glossary Bibliography Other factor deficiencies Factor I deficiency Fibrinogen deficiency Factor II deficiency Prothrombin deficiency Factor V deficiency Combined factor V and factor VIII deficiency Factor VII deficiency Factor X deficiency Factor XI deficiency Hemophilia C Factor XII deficiency Factor XIII deficiency Summary Chart Platelet function disorders Introduction Symptoms of platelet function disorders Diagnosis of platelet function disorders Types of platelet function disorders Treatment of platelet function disorders Precautions PDF documents Clotting factor concentrates Women Inherited bleeding disorders affecting women Symptoms Diagnosis Inheritance Medical treatment options for menorrhagia and other symptoms Gynaecological treatment options for menorrhagia Precautions for pregnant women Staying healthy Bleeding disorder treatment centres Educational resources Stories from women and girls who bleed too much About the CHS Support and Education Passport to well being Destination fitness Home care The road to independence Roadmap for managing pain Navigating the emergency department Bon Voyage Travelling with a bleeding disorder Charting Your Course PEP Parents Empowering Parents program Vocational assessment tool Career planning and scholarship links Scholarship Program Federal and Provincial Support Programs Insurance coverage Educational Material Printed documents Bleeding disorders in women Carriers of hemophilia A or B Hemophilia Hepatitis C HIV Inhibitors Physical activity and sports Platelet function disorders Rare factor deficiencies Relevant to all bleeding disorders Resources for children Von Willebrand disease Videos Care and Treatment Emergency Care Pain Management Nursing Physiotherapy Introduction Constitution of the Canadian Physiotherapists in Hemophilia Care CPHC Standards of Physiotherapy Care and Assessment Selected Journal Articles Educational material Bibliography Other resources Social Work Community Partners and Links Practice Guidelines Mission Services Interventions Standards of Practice Comprehensive Care Standards Safe Secure Blood Supply Products in the pipeline CHS Policy on Paid Plasma Donations Report Cards on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014

    Original URL path: http://www.hemophilia.ca/en/about-the-chs/case-for-support/ (2014-10-09)
    Open archived version from archive

  • The Canadian Hemophilia Society at a Glance - Canadian Hemophilia Society
    Standards of Physiotherapy Care and Assessment Selected Journal Articles Educational material Bibliography Other resources Social Work Community Partners and Links Practice Guidelines Mission Services Interventions Standards of Practice Comprehensive Care Standards Safe Secure Blood Supply Products in the pipeline CHS Policy on Paid Plasma Donations Report Cards on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment Centre partnerships ended recently Canadian Hemophilia Society International Projects Fund Canadian Organizational Twins Recently closed twinning partnerships Treatment Centres British Columbia Alberta Saskatchewan Manitoba Ontario Quebec New Brunswick Prince Edward Island Nova Scotia Newfoundland and Labrador HCV HIV Hepatitis C and HIV Compensation I am a survivor HCV treatment support for 1986 1990 claimants National Endowment Fund Scholarship University of Ottawa Criminalization of HIV Non Disclosure HIV Know your rights US travel ban lifted World Hepatitis Day Recommendations for a Canadian Hepatitis C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards

    Original URL path: http://www.hemophilia.ca/en/about-the-chs/case-for-support/the-canadian-hemophilia-society-at-a-glance/ (2014-10-09)
    Open archived version from archive